Correction to: Leukemia (2017) 31, 1023–1038; doi:10.1038/leu.2017.43; published online 17 February 2017
Following the publication of this article, the editors noted that Janus should be capitalized. The corrected title appears above.
Additional information
The online version of the original article can be found at 10.1038/leu.2017.43
Rights and permissions
About this article
Cite this article
Leroy, E., Constantinescu, S. Erratum: Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition. Leukemia 31, 2853 (2017). https://doi.org/10.1038/leu.2017.158
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.158
This article is cited by
-
Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
npj Precision Oncology (2021)
-
Ocular Toxicity of Targeted Anticancer Agents
Drugs (2021)
-
Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models
Scientific Reports (2019)
